Ignite Creation Date:
2024-07-17 @ 11:09 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06493019
Status:
RECRUITING
Last Update Posted:
2024-07-09
First Post:
2024-06-17
Brief Title:
Study of Pembrolizumab Carboplatin Paclitaxel and Radiation for the Treatment of Early-Stage Anal Cancer
Sponsor:
Dustin Deming
Organization:
Hoosier Cancer Research Network
Study Overview
Official Title:
A Phase II Study of Pembrolizumab Carboplatin Paclitaxel and Radiation for the Treatment of Early-Stage Anal Cancer
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A single arm phase II study of pembrolizumab carboplatin paclitaxel and radiation for the treatment of early-stage anal cancer There are 2 treatments phases and then surveillance The first treatment phase is the chemoradiation phase Cycle 1-6 weekly cycles which is followed by the maintenance phase Cycle 7-14 6 week cycles
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None